Search Results for keywords:"disease transmission"

The Food and Drug Administration (FDA) has released new guidance aimed at reducing the risk of disease transmission caused by sepsis in human cell and tissue products. This guidance is designed to help organizations that make donor eligibility decisions by recommending practices to lower infection risks. The FDA issued this guidance immediately due to urgent health concerns, updating previous recommendations from 2007. The guidance reflects the FDA's current viewpoints but does not impose any legal obligations.

The Food and Drug Administration (FDA) has released revised final guidances to minimize the risk of spreading disease agents like sepsis and Mycobacterium tuberculosis through human cells, tissues, and related products. The guidances originally advised establishments to implement recommendations within four weeks, but now suggest a longer timeframe until May 4, 2025, to allow for further review and consideration of public comments. These changes follow a presidential directive for regulatory review, prioritizing public health while seeking further input. The FDA emphasizes that these updates are being implemented immediately, even as they remain open to additional public comments.

The National Institutes of Health (NIH), under the Department of Health and Human Services, announced closed meetings for various committees of the Center for Scientific Review. These meetings, held virtually, aim to discuss and evaluate grant applications related to several research topics, including transmission of diseases, cardiovascular and hematology activities, vascular physiology, and drug delivery systems. The meetings are not open to the public to protect confidential information and personal privacy. Meeting dates range from May 19 to June 24, 2025.